NASDAQ:CERS - Cerus Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$6.43 -0.07 (-1.08 %)
(As of 05/23/2018 08:52 AM ET)
Previous Close$6.50
Today's Range$6.43 - $6.59
52-Week Range$1.93 - $6.79
Volume616,130 shs
Average Volume1.06 million shs
Market Capitalization$848.54 million
P/E Ratio-11.48
Dividend YieldN/A
Beta1.72

About Cerus (NASDAQ:CERS)

Cerus logoCerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System is based on its proprietary technology for controlling biological replication; and targets and inactivates blood-borne pathogens, such as viruses, bacteria, and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products. The company's INTERCEPT Blood Systems for platelets and plasma are designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion. It markets platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was founded in 1991 and is headquartered in Concord, California.

Receive CERS News and Ratings via Email

Sign-up to receive the latest news and ratings for CERS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
SymbolNASDAQ:CERS
CUSIP15708510
Phone925-288-6000

Debt

Debt-to-Equity Ratio0.33
Current Ratio5.66
Quick Ratio5.10

Price-To-Earnings

Trailing P/E Ratio-11.48
Forward P/E Ratio-14.29
P/E GrowthN/A

Sales & Book Value

Annual Sales$43.57 million
Price / Sales19.26
Cash FlowN/A
Price / CashN/A
Book Value$0.66 per share
Price / Book9.74

Profitability

EPS (Most Recent Fiscal Year)($0.56)
Net Income$-60,580,000.00
Net Margins-111.46%
Return on Equity-111.19%
Return on Assets-52.81%

Miscellaneous

Employees215
Outstanding Shares130,540,000

Cerus (NASDAQ:CERS) Frequently Asked Questions

What is Cerus' stock symbol?

Cerus trades on the NASDAQ under the ticker symbol "CERS."

How were Cerus' earnings last quarter?

Cerus Co. (NASDAQ:CERS) posted its quarterly earnings results on Tuesday, May, 8th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.12) by $0.01. The biotechnology company had revenue of $13.56 million for the quarter, compared to analyst estimates of $12.22 million. Cerus had a negative return on equity of 111.19% and a negative net margin of 111.46%. The business's revenue was up 93.4% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.18) EPS. View Cerus' Earnings History.

When is Cerus' next earnings date?

Cerus is scheduled to release their next quarterly earnings announcement on Thursday, August, 2nd 2018. View Earnings Estimates for Cerus.

What price target have analysts set for CERS?

4 analysts have issued 1-year price targets for Cerus' shares. Their forecasts range from $5.00 to $6.00. On average, they anticipate Cerus' share price to reach $5.25 in the next twelve months. View Analyst Ratings for Cerus.

What are Wall Street analysts saying about Cerus stock?

Here are some recent quotes from research analysts about Cerus stock:
  • 1. According to Zacks Investment Research, "Cerus Corporation is developing medical products based on a platform technology that prevents nucleic acid replication. The company's initial application of this technology is the development of systems to inactivate viruses, bacteria and other pathogens in blood components used for transfusion. The company is also focusing research and development efforts on other potential health care applications for this platform technology, including pathogen inactivation of source plasma used for fractionation, improving the outcomes of stem cell transplantation. " (5/14/2018)
  • 2. Cantor Fitzgerald analysts commented, "This afternoon, CERS announced that its Ph 3 transfusion study (SPARC) evaluating its INTERCEPT-treated red blood cells in thalassemia (chronic anemia) patients achieved its primary efficacy and safety endpoints." (1/23/2018)

Who are some of Cerus' key competitors?

Who are Cerus' key executives?

Cerus' management team includes the folowing people:
  • Mr. William M. Greenman, Pres, CEO & Director (Age 51)
  • Dr. Laurence M. Corash, Co-Founder, Chief Scientific Officer, Sr. VP & Corp. Director (Age 74)
  • Mr. Kevin D. Green, VP of Fin. & CFO (Age 46)
  • Ms. Chrystal N. Menard, Chief Legal Officer and Gen. Counsel (Age 47)
  • Dr. Richard J. Benjamin, Chief Medical Officer (Age 58)

Has Cerus been receiving favorable news coverage?

News coverage about CERS stock has trended somewhat positive on Wednesday, according to Accern Sentiment Analysis. Accern identifies negative and positive media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cerus earned a news impact score of 0.12 on Accern's scale. They also gave news stories about the biotechnology company an impact score of 46.23 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term.

Who are Cerus' major shareholders?

Cerus' stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.27%), Elk Creek Partners LLC (5.41%), Senvest Management LLC (3.11%), Millennium Management LLC (1.33%), Northern Trust Corp (1.12%) and Bamco Inc. NY (0.72%). Company insiders that own Cerus stock include Carol Moore, Chrystal Menard, Kevin Dennis Green, Laurence M Corash, Richard J Benjamin and William Mariner Greenman. View Institutional Ownership Trends for Cerus.

Which institutional investors are selling Cerus stock?

CERS stock was sold by a variety of institutional investors in the last quarter, including Bamco Inc. NY, A.R.T. Advisors LLC, BB&T Securities LLC and Millrace Asset Group Inc.. Company insiders that have sold Cerus company stock in the last year include Carol Moore, Chrystal Menard, Kevin Dennis Green, Richard J Benjamin and William Mariner Greenman. View Insider Buying and Selling for Cerus.

Which institutional investors are buying Cerus stock?

CERS stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Senvest Management LLC, Millennium Management LLC, Elk Creek Partners LLC, JPMorgan Chase & Co., Northern Trust Corp, Schwab Charles Investment Management Inc. and Alambic Investment Management L.P.. View Insider Buying and Selling for Cerus.

How do I buy shares of Cerus?

Shares of CERS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cerus' stock price today?

One share of CERS stock can currently be purchased for approximately $6.43.

How big of a company is Cerus?

Cerus has a market capitalization of $848.54 million and generates $43.57 million in revenue each year. The biotechnology company earns $-60,580,000.00 in net income (profit) each year or ($0.56) on an earnings per share basis. Cerus employs 215 workers across the globe.

How can I contact Cerus?

Cerus' mailing address is 2550 STANWELL DRIVE, CONCORD CA, 94520. The biotechnology company can be reached via phone at 925-288-6000 or via email at [email protected]


MarketBeat Community Rating for Cerus (CERS)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  388 (Vote Outperform)
Underperform Votes:  222 (Vote Underperform)
Total Votes:  610
MarketBeat's community ratings are surveys of what our community members think about Cerus and other stocks. Vote "Outperform" if you believe CERS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CERS will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Cerus (NASDAQ:CERS) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for Cerus in the last 12 months. Their average twelve-month price target is $5.25, suggesting that the stock has a possible downside of 18.35%. The high price target for CERS is $6.00 and the low price target for CERS is $5.00. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.752.752.803.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $5.25$5.25$6.20$7.00
Price Target Upside: 18.35% downside7.80% upside23.75% upside131.79% upside

Cerus (NASDAQ:CERS) Consensus Price Target History

Price Target History for Cerus (NASDAQ:CERS)

Cerus (NASDAQ:CERS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/9/2018BTIG ResearchReiterated RatingHoldHighView Rating Details
1/23/2018Cantor FitzgeraldReiterated RatingBuy$5.00HighView Rating Details
12/1/2017Robert W. BairdReiterated RatingBuy$5.00LowView Rating Details
10/5/2017CowenSet Price TargetBuy$6.00N/AView Rating Details
3/8/2017FBR & CoSet Price TargetBuy$10.00LowView Rating Details
(Data available from 5/23/2016 forward)

Earnings

Cerus (NASDAQ:CERS) Earnings History and Estimates Chart

Earnings by Quarter for Cerus (NASDAQ:CERS)

Cerus (NASDAQ:CERS) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.45 EPS
Next Year EPS Consensus Estimate: $-0.38 EPS

Cerus (NASDAQ CERS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/2/2018        
5/8/2018Q1($0.12)($0.11)$12.22 million$13.56 millionViewN/AView Earnings Details
3/8/2018Q4 2017($0.11)($0.10)$17.53 million$16.20 millionViewListenView Earnings Details
11/2/2017Q3 2017($0.15)($0.12)$11.95 million$10.80 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.16)($0.16)$9.14 million$9.53 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.1650)($0.18)$8.98 million$7.01 millionViewListenView Earnings Details
3/7/2017Q4 2016($0.16)($0.13)$11.29 million$10.10 millionViewListenView Earnings Details
11/3/2016Q316($0.17)($0.14)$10.34 million$10.20 millionViewN/AView Earnings Details
8/4/2016Q216($0.17)($0.18)$8.88 million$9.25 millionViewN/AView Earnings Details
5/3/2016Q1($0.16)($0.17)$8.29 million$7.60 millionViewN/AView Earnings Details
3/8/2016Q415($0.16)($0.15)$9.72 million$9.70 millionViewListenView Earnings Details
11/5/2015Q315($0.16)($0.17)$10.00 million$8.04 millionViewN/AView Earnings Details
8/6/2015Q215($0.15)($0.17)$8.71 million$8.83 millionViewN/AView Earnings Details
5/5/2015Q214($0.16)($0.21)$7.70 million$7.70 millionViewN/AView Earnings Details
2/26/2015Q114($0.15)($0.25)$10.36 million$9.70 millionViewN/AView Earnings Details
11/4/2014Q413($0.13)($0.15)$9.83 million$10.36 millionViewN/AView Earnings Details
7/31/2014Q313($0.13)($0.16)$8.17 million$8.60 millionViewN/AView Earnings Details
5/1/2014Q313($0.09)($0.04)$9.65 million$7.86 millionViewN/AView Earnings Details
2/25/2014Q213($0.09)($0.10)$11.77 million$9.23 millionViewN/AView Earnings Details
10/29/2013($0.09)($0.29)$10.34 million$10.54 millionViewN/AView Earnings Details
7/30/2013Q2 2013($0.09)($0.10)$10.45 million$10.15 millionViewN/AView Earnings Details
4/30/2013Q1 2013($0.08)($0.11)$9.96 million$9.73 millionViewN/AView Earnings Details
2/28/2013Q4 2012($0.08)($0.11)ViewN/AView Earnings Details
11/7/2012Q3 2012($0.08)($0.10)ViewN/AView Earnings Details
8/2/2012Q2 2012($0.08)($0.17)ViewN/AView Earnings Details
5/1/2012Q1 2012($0.08)($0.08)ViewN/AView Earnings Details
2/28/2012Q4 2011($0.08)($0.09)ViewN/AView Earnings Details
11/1/2011Q3 2011($0.10)($0.06)ViewN/AView Earnings Details
7/28/2011Q2 2011($0.10)($0.13)ViewN/AView Earnings Details
4/28/2011Q1 2011($0.09)($0.11)ViewN/AView Earnings Details
3/3/2011Q4 2010($0.07)($0.05)ViewN/AView Earnings Details
10/28/2010Q3 2010($0.09)($0.10)ViewN/AView Earnings Details
7/29/2010Q2 2010($0.11)($0.14)ViewN/AView Earnings Details
4/29/2010Q1 2010($0.10)($0.13)ViewN/AView Earnings Details
2/23/2010Q4 2009($0.12)($0.13)ViewN/AView Earnings Details
10/29/2009Q3 2009($0.12)($0.16)ViewN/AView Earnings Details
7/30/2009Q2 2009($0.16)($0.19)ViewN/AView Earnings Details
4/30/2009Q1 2009($0.18)($0.21)ViewN/AView Earnings Details
2/26/2009Q4 2008($0.24)($0.20)ViewN/AView Earnings Details
10/30/2008Q3 2008($0.27)($0.27)ViewN/AView Earnings Details
7/31/2008Q2 2008($0.26)($0.28)ViewN/AView Earnings Details
5/1/2008Q1 2008($0.26)($0.16)ViewN/AView Earnings Details
2/21/2008Q4 2007($0.25)($0.32)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Cerus (NASDAQ:CERS) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Cerus (NASDAQ CERS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 6.80%
Institutional Ownership Percentage: 60.14%
Insider Trading History for Cerus (NASDAQ:CERS)
Institutional Ownership by Quarter for Cerus (NASDAQ:CERS)

Cerus (NASDAQ CERS) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/17/2018Kevin Dennis GreenCFOSell73,000$6.42$468,660.0083,825View SEC Filing  
5/11/2018Carol MooreSVPSell60,841$6.26$380,864.6660,841View SEC Filing  
5/11/2018Richard J. BenjaminInsiderSell8,631$6.69$57,741.39View SEC Filing  
3/15/2018Laurence M CorashInsiderBuy150,011$5.15$772,556.651,462,580View SEC Filing  
3/13/2018Carol MooreSVPSell2,623$5.05$13,246.15View SEC Filing  
3/12/2018Chrystal MenardinsiderSell1,960$4.80$9,408.004,832View SEC Filing  
3/12/2018Kevin Dennis GreenCFOSell2,063$4.80$9,902.4058,062View SEC Filing  
3/12/2018William Mariner GreenmanCEOSell7,735$4.80$37,128.00View SEC Filing  
8/11/2017Laurence M CorashInsiderBuy92,796$2.45$227,350.201,375,711View SEC Filing  
3/15/2017Kevin Dennis GreenCFOSell2,343$4.21$9,864.03View SEC Filing  
3/15/2017William Mariner GreenmanInsiderSell8,786$4.21$36,989.06View SEC Filing  
3/14/2017Carol MooreSVPSell2,377$4.15$9,864.55View SEC Filing  
3/14/2017Richard J BenjaminInsiderSell1,189$4.15$4,934.353,000View SEC Filing  
8/22/2016Kevin Dennis GreenCFOSell17,150$6.80$116,620.00View SEC Filing  
8/19/2015Laurence M CorashInsiderBuy25,900$4.99$129,241.001,270,256View SEC Filing  
8/18/2015Laurence M CorashInsiderBuy84,600$4.77$403,542.00View SEC Filing  
11/10/2014William Mariner GreenmanCEOBuy21,800$3.93$85,674.00View SEC Filing  
11/19/2012William Mariner GreenmanCEOBuy3,200$3.02$9,664.00View SEC Filing  
11/16/2012Laurence M CorashInsiderBuy2,000$2.85$5,700.00View SEC Filing  
11/16/2012William Mariner GreenmanCEOBuy13,800$2.85$39,330.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Cerus (NASDAQ CERS) News Headlines

Source:
DateHeadline
Insider Selling: Cerus Co. (CERS) CFO Sells 73,000 Shares of StockInsider Selling: Cerus Co. (CERS) CFO Sells 73,000 Shares of Stock
www.americanbankingnews.com - May 18 at 7:55 PM
Cerus nabs $15M government contractCerus nabs $15M government contract
seekingalpha.com - May 17 at 6:04 PM
Cerus (CERS) Reports Additional BARDA Funding to Support Development of INTERCEPT Blood System for Red ...Cerus (CERS) Reports Additional BARDA Funding to Support Development of INTERCEPT Blood System for Red ...
www.streetinsider.com - May 17 at 8:36 AM
Cerus Announces Additional BARDA Funding to Support Development of INTERCEPT Blood System for Red Blood CellsCerus Announces Additional BARDA Funding to Support Development of INTERCEPT Blood System for Red Blood Cells
finance.yahoo.com - May 16 at 5:25 PM
New Research Coverage Highlights Cerus, Health Insurance Innovations, Tetra Tech, Ferro, Dril-Quip, and MSC ...New Research Coverage Highlights Cerus, Health Insurance Innovations, Tetra Tech, Ferro, Dril-Quip, and MSC ...
globenewswire.com - May 15 at 8:46 AM
New Research Coverage Highlights Cerus, Health Insurance Innovations, Tetra Tech, Ferro, Dril-Quip, and MSC Industrial Direct — Consolidated Revenues, Company Growth, and Expectations for 2018New Research Coverage Highlights Cerus, Health Insurance Innovations, Tetra Tech, Ferro, Dril-Quip, and MSC Industrial Direct — Consolidated Revenues, Company Growth, and Expectations for 2018
finance.yahoo.com - May 15 at 8:46 AM
Richard J. Benjamin Sells 8,631 Shares of Cerus Co. (CERS) StockRichard J. Benjamin Sells 8,631 Shares of Cerus Co. (CERS) Stock
www.americanbankingnews.com - May 14 at 10:12 PM
Insider Selling: Cerus Co. (CERS) SVP Sells 60,841 Shares of StockInsider Selling: Cerus Co. (CERS) SVP Sells 60,841 Shares of Stock
www.americanbankingnews.com - May 14 at 10:12 PM
Zacks Investment Research Lowers Cerus (CERS) to SellZacks Investment Research Lowers Cerus (CERS) to Sell
www.americanbankingnews.com - May 14 at 8:10 PM
Cerus Endovascular Promotes Stephen Griffin, PhD, to PresidentCerus Endovascular Promotes Stephen Griffin, PhD, to President
www.prnewswire.com - May 11 at 8:48 AM
Cerus (CERS) Hold Rating Reaffirmed at BTIG ResearchCerus' (CERS) Hold Rating Reaffirmed at BTIG Research
www.americanbankingnews.com - May 10 at 9:08 AM
Edited Transcript of CERS earnings conference call or presentation 8-May-18 8:15pm GMTEdited Transcript of CERS earnings conference call or presentation 8-May-18 8:15pm GMT
finance.yahoo.com - May 9 at 5:21 PM
Here's Why Cerus Corporation Stock Is Surging TodayHere's Why Cerus Corporation Stock Is Surging Today
finance.yahoo.com - May 9 at 5:21 PM
Heres Why Cerus Corporation Stock Is Surging TodayHere's Why Cerus Corporation Stock Is Surging Today
www.fool.com - May 9 at 2:52 PM
Cerus (CERS) CEO Obi Greenman on Q1 2018 Results - Earnings Call TranscriptCerus' (CERS) CEO Obi Greenman on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 9 at 8:33 AM
BRIEF-Cerus Corp Reports Q1 Loss Per Share $0.11BRIEF-Cerus Corp Reports Q1 Loss Per Share $0.11
www.reuters.com - May 9 at 8:33 AM
Cerus: 1Q Earnings SnapshotCerus: 1Q Earnings Snapshot
finance.yahoo.com - May 9 at 8:33 AM
Cerus (CERS) Issues Quarterly  Earnings ResultsCerus (CERS) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 8 at 10:30 PM
Cerus Corporation Reports First Quarter 2018 ResultsCerus Corporation Reports First Quarter 2018 Results
finance.yahoo.com - May 8 at 5:25 PM
Cerus (CERS) Upgraded at ValuEngineCerus (CERS) Upgraded at ValuEngine
www.americanbankingnews.com - May 5 at 2:27 PM
Cerus to Present at the Deutsche Bank 43rd Annual Health Care Conference on Wednesday May 9, 2018Cerus to Present at the Deutsche Bank 43rd Annual Health Care Conference on Wednesday May 9, 2018
finance.yahoo.com - May 3 at 5:13 PM
Cerus (CERS) to Release Quarterly Earnings on TuesdayCerus (CERS) to Release Quarterly Earnings on Tuesday
www.americanbankingnews.com - May 1 at 11:26 AM
Cerus Co. (CERS) Given Average Rating of "Buy" by BrokeragesCerus Co. (CERS) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - April 29 at 9:20 AM
Cerus (CERS) Cut to "Buy" at BidaskClubCerus (CERS) Cut to "Buy" at BidaskClub
www.americanbankingnews.com - April 28 at 8:34 AM
BRIEF-Cerus Announces Health Canada Approval Of The Intercept Blood System For PlateletsBRIEF-Cerus Announces Health Canada Approval Of The Intercept Blood System For Platelets
www.reuters.com - April 25 at 5:20 PM
Cerus to Release First Quarter 2018 Results on May 8, 2018Cerus to Release First Quarter 2018 Results on May 8, 2018
finance.yahoo.com - April 25 at 5:20 PM
Cerus Announces Health Canada Approval of the INTERCEPT Blood System for PlateletsCerus Announces Health Canada Approval of the INTERCEPT Blood System for Platelets
finance.yahoo.com - April 25 at 5:20 PM
Two trendy condo projects aim to provide urban living at cheaper price tagTwo trendy condo projects aim to provide urban living at cheaper price tag
www.bizjournals.com - April 23 at 5:04 PM
Reviewing Cerus (CERS) and Nevro (NVRO)Reviewing Cerus (CERS) and Nevro (NVRO)
www.americanbankingnews.com - April 20 at 3:13 AM
Cerus (CERS) Lowered to "Hold" at Zacks Investment ResearchCerus (CERS) Lowered to "Hold" at Zacks Investment Research
www.americanbankingnews.com - April 13 at 7:13 PM
Cerus (CERS) Lifted to "Hold" at BidaskClubCerus (CERS) Lifted to "Hold" at BidaskClub
www.americanbankingnews.com - April 12 at 6:47 PM
Zacks Investment Research Upgrades Cerus (CERS) to "Buy"Zacks Investment Research Upgrades Cerus (CERS) to "Buy"
www.americanbankingnews.com - April 10 at 1:42 PM
Cerus (CERS) Upgraded to Buy by Zacks Investment ResearchCerus (CERS) Upgraded to Buy by Zacks Investment Research
www.americanbankingnews.com - April 4 at 8:32 PM
Cerus Co. (CERS) Given Average Rating of "Buy" by AnalystsCerus Co. (CERS) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - April 4 at 9:32 AM
Cerus (CERS) Downgraded by Zacks Investment ResearchCerus (CERS) Downgraded by Zacks Investment Research
www.americanbankingnews.com - April 3 at 8:45 PM
BRIEF-Cerus Redes Phase 3 Red Blood Cell Study Expands Into The Continental USBRIEF-Cerus' Redes Phase 3 Red Blood Cell Study Expands Into The Continental US
www.reuters.com - April 2 at 8:57 AM
Cerus (CERS) Announces RedeS Phase 3 Red Blood Cell Study Expands Into Continental USCerus (CERS) Announces RedeS Phase 3 Red Blood Cell Study Expands Into Continental US
www.streetinsider.com - April 2 at 8:57 AM
Cerus RedeS Phase 3 Red Blood Cell Study Expands Into the Continental USCerus' RedeS Phase 3 Red Blood Cell Study Expands Into the Continental US
www.businesswire.com - April 2 at 8:57 AM
Cerus’ RedeS Phase 3 Red Blood Cell Study Expands Into the Continental U.S.Cerus’ RedeS Phase 3 Red Blood Cell Study Expands Into the Continental U.S.
finance.yahoo.com - April 2 at 8:57 AM
Blood transfusion company inks deal for new East Bay headquartersBlood transfusion company inks deal for new East Bay headquarters
finance.yahoo.com - March 28 at 5:09 PM
Cerus (CERS) Given Buy Rating at Cantor FitzgeraldCerus (CERS) Given Buy Rating at Cantor Fitzgerald
www.americanbankingnews.com - March 26 at 6:30 PM
Cerus (CERS) Stock Rating Upgraded by BidaskClubCerus (CERS) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - March 24 at 1:11 PM
Cerus Corporation, Shares Up 39% in the Past Month, Analysts Review, INTERCEPTCerus Corporation, Shares Up 39% in the Past Month, Analysts Review, INTERCEPT
finance.yahoo.com - March 22 at 8:42 AM
Cerus (CERS) Looks Good: Stock Adds 9.5% in Session - NasdaqCerus (CERS) Looks Good: Stock Adds 9.5% in Session - Nasdaq
www.nasdaq.com - March 20 at 8:44 AM
Cerus (CERS) Upgraded to "Strong-Buy" at BidaskClubCerus (CERS) Upgraded to "Strong-Buy" at BidaskClub
www.americanbankingnews.com - March 17 at 6:44 PM
Wired News – FDA Accepted Tyme’s IND Application to Begin Phase-II Clinical Study for SM-88 in Pancreatic CancerWired News – FDA Accepted Tyme’s IND Application to Begin Phase-II Clinical Study for SM-88 in Pancreatic Cancer
finance.yahoo.com - March 16 at 8:34 AM
Insider Buying: Cerus Co. (CERS) Insider Buys 150,011 Shares of StockInsider Buying: Cerus Co. (CERS) Insider Buys 150,011 Shares of Stock
www.americanbankingnews.com - March 15 at 7:46 PM
Is Cerus Corporation’s (NASDAQ:CERS) Balance Sheet A Threat To Its Future?Is Cerus Corporation’s (NASDAQ:CERS) Balance Sheet A Threat To Its Future?
finance.yahoo.com - March 15 at 8:30 AM
Cerus (CERS) Upgraded to "Hold" at ValuEngineCerus (CERS) Upgraded to "Hold" at ValuEngine
www.americanbankingnews.com - March 15 at 12:28 AM
Cerus (CERS) Upgraded to "Hold" by Zacks Investment ResearchCerus (CERS) Upgraded to "Hold" by Zacks Investment Research
www.americanbankingnews.com - March 14 at 7:16 PM

SEC Filings

Cerus (NASDAQ:CERS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Cerus (NASDAQ:CERS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Cerus (NASDAQ CERS) Stock Chart for Wednesday, May, 23, 2018

Loading chart…

This page was last updated on 5/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.